Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- ASCO 2020: Abstract Recommendations From Dr. Lee Schwartzberg for Breast Cancer
- Management of Adverse Events With Alpelisib Plus Fulvestrant in Patients With HR+ Advanced Breast Cancer
- AACR: Novel Agent Shows Promise As Immunotherapy Combination in TPN Breast Cancer
- AACR: Mature Data on Utility of PARP Inhibitors in Advanced Breast Cancer
- Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and Vomiting
- AACR: Provocative Data on Neoadjuvant Checkpoint Inhibition and PARP Inhibition for Breast Cancer
- AACR 2020: Addition of Durvalumab and Olaparib to Paclitaxel Increases Response Rates in Breast Cancer
- FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients With HER2-Positive Metastatic Breast Cancer
- Patient-Reported Outcomes With Adjuvant T-DM1 vs Trastuzumab in Patients With Residual Invasive Disease After Neoadjuvant Therapy for HER2+ Breast Cancer
- Guidelines for the Management of Hereditary Breast Cancer